AGO DESKTOP III/ENGOT-ov20: Impact of secondary cytoreductive surgery in recurrent ovarian cancer

Bookmark and Share
Published: 12 Jun 2020
Views: 127
Prof Andreas du Bois - Kliniken Essen Mitte, Essen, Germany

Prof Andreas du Bois speaks to ecancer about the final analysis from the AGO DESKTOP III/ENGOT-ov20 study looking at the impact of secondary cytoreductive surgery in recurrent ovarian cancer presented at the ASCO virtual meeting 2020.

He explains that patients selected were those who had relapsed ovarian cancer with a treatment free interval of over 6 months and a positive AGO DESKTOP score.

They were then randomised between surgery or no surgery with all patients receiving standard platinum combination chemotherapy.

Prof du Bois reports that around 75% of patients had a complete resection with these patients seeing a median 16 months longer survival than patients not offered the surgery.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.